Disclosures. Committee on Blood and Blood Products) Co-investigator CBS Small Project. in Solid Organ Transplant Recipients

Similar documents
CTYOMEGALOVIRUS (CMV) - BACKGROUND

GUIDELINES FOR IRRADIATED BLOOD COMPONENTS

Specific Requirements

Transfusion-transmitted Cytomegalovirus

Preventing CMV Transmission through Leukodepletion

Blood Product Modifications: Leukofiltration, Irradiation and Washing

A Review of Guidelines and Evidence for the Use of Irradiated Blood Products in Solid Tumor, Chemotherapy Patients. Chris Kim 11/29/12

RECOMMENDATIONS FOR USE OF IRRADIATED BLOOD COMPONENTS IN CANADA

Guidelines for Gamma Irradiation of Blood Components

Special Requirements Lab Matters. 21 st June Barrie Ferguson

Carol Cantwell Blood Transfusion Laboratory Manager St Mary s Hospital, ICHNT

Transfusion-associated graft-versus-host disease

Special Requirements Lab Matters. 18 th May Katy Cowan PBM Practitioner NHSBT

Criteria for the Use of CMV Seronegative Blood

GUIDELINES FOR THE TRANSFUSION OF BLOOD COMPONENTS

Consent Laboratory Transfuse RBC

Non-Medical Authorisation Course

Congenital Cytomegalovirus (CMV)

All institutions that transfuse blood components and products should implement national and local policies and written procedures for:

with special requirements Contributes to: CQC Regulation 12 Consulted With Individual/Body Date Lead

Blood & Blood Product Administration

Blood is serious business

Blood Components & Indications for Transfusion. Neda Kalhor

Postnatal cytomegalovirus infection: a pilot comparative effectiveness study of transfusion safety using leukoreduced-only transfusion strategy

Riposta immune versus stato immune

LifeBridge Health Transfusion Service Sinai Hospital of Baltimore Northwest Hospital Center BQA Transfusion Criteria Version#2 POLICY NO.

Policy for the use of Irradiated blood products

UKGS TRANSFUSION SERVICE PRODUCTS AND AVAILABILITY

ADULT TRANSFUSION GUIDELINES ORDERED COMPONENT

BLOOD TRANSFUSION. Dr Lumka Ntabeni

Summary of Changes Page BMT CTN 1205 Protocol Amendment #4 (Version 5.0) Dated July 22, 2016

Transfusion-Associated Graft-versus-Host Disease TRANSFUSION-ASSOCIATED GRAFT-VERSUS-HOST DISEASE

Great Ormond Street Hospital for Children. Patient Transfer. Penny Eyton-Jones TLM, Great Ormond Street NHS Foundation Trust

Blood Transfusion Guidelines in Clinical Practice

The role of HLA in Allogeneic Hematopoietic Stem Cell Transplantation and Platelet Refractoriness.

Guidelines for the Management of Platelet Transfusion Refractoriness GUIDELINES FOR THE MANAGEMENT OF PLATELET TRANSFUSION REFRACTORINESS

Corporate Medical Policy

Survey on Transfusion-Transmitted Cytomegalovirus and Cytomegalovirus Disease Mitigation

Blood Transfusion. What is blood transfusion? What are blood banks? When is a blood transfusion needed? Who can donate blood?

PUO in the Immunocompromised Host: CMV and beyond

Disclosures. Newborn Screening for Severe Combined Immune Deficiency Syndromes (SCIDS): Why; why now? Learning objectives.

Hot topics in Paediatric Transfusion and the Emergency Provision from the Blood Transfusion Laboratory. Margaret Slade

Hepatitis E and the English blood supply

An Overview of Blood and Marrow Transplantation

Apheresis: Transfusion Indications. Sasha Wilson: Transfusion Senior Nurse

One Day BMT Course by Thai Society of Hematology. Management of Graft Failure and Relapsed Diseases

Regulatory Status FDA-approved indications: Valcyte is a deoxynucleoside analogue cytomegalovirus (CMV) DNA polymerase inhibitor indicated for: (1)

Disclosures. CMV and EBV Infection in Pediatric Transplantation. Goals. Common Aspects CMV (Cytomegalovirus) and EBV (Epstein-Barr virus)

IN UTERO HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CANINES: THE GESTATIONAL WINDOW OF OPPORTUNITY TO MAXIMIZE ENGRAFTMENT

An Approach to the Patient Refractory to Platelets Transfusion. Harold Alvarez, MD

The Study of Congenital Infections. A/Prof. William Rawlinson Dr. Sian Munro

HEADACHES AFTER Bone Marrow Transplant

Corporate Medical Policy

CHAPTER 3 LABORATORY PROCEDURES

Congenital CMV infection. Infectious and Tropical Pediatric Division Department of Child Health Medical Faculty, University of Sumatera Utara

IMMUNIZATION IN CHILDREN WITH CANCER

Blood transfusion. Dr. J. Potgieter Dept. of Haematology NHLS - TAD

Case-Control Study: ABO-Incompatible Plasma Causing Hepatic Veno-Occlusive Disease in HSCT

1. Introduction. Correspondence should be addressed to Richard J. Drew; Received 23 July 2015; Accepted 15 November 2015

What are stem cells? A stem cell can differentiate into any one of 220 different specialised cells in the body STEM CELLS

COMPONENT SECTION MANUAL THE PROCEDURE FOR THE PREPARATION OF WHOLE BLOOD FOR NEONATAL EXCHANGE TRANSFUSION

Copyright information:

New recommendations for immunocompromised patients

Acknowledgements. Department of Hematological Malignancy and Cellular Therapy, University of Kansas Medical Center

PRACTICE GUIDELINES WOMEN S HEALTH PROGRAM

For more information about how to cite these materials visit

Immunodeficiencies HIV/AIDS

Maternofoetal transfer of Cytomegalovirus IgG antibodies in Maiduguri, North Eastern Nigeria

European Society of Anaesthesiologists CLINICAL CONSEQUENCES OF LEUKOCYTE REDUCTION

5/9/2018. Bone marrow failure diseases (aplastic anemia) can be cured by providing a source of new marrow

Definitions of Current SHOT Categories & What to Report

Corporate Medical Policy

Paediatric Transfusion Guidelines

Blood and Marrow Transplant (BMT) for Sickle Cell Disease

General Terms: Appendix B. National Marrow Donor Program and The Medical College of Wisconsin

Setting The setting was secondary care. The economic analysis was carried out in Canada.

Relevant Communicable Diseases in HCT/Ps

Severe Combined Immune Deficiency (SCID) A Guide for Parents Following a Diagnosis

Patient Input CADTH COMMON DRUG REVIEW

BMTCN REVIEW COURSE PRE-TRANSPLANT CARE

Federica Galaverna, 1 Daria Pagliara, 1 Deepa Manwani, 2 Rajni Agarwal-Hashmi, 3 Melissa Aldinger, 4 Franco Locatelli 1

The National Marrow Donor Program. Graft Sources for Hematopoietic Cell Transplantation. Simon Bostic, URD Transplant Recipient

CORD BLOOD TRANSPLANTATION STUDY CBU EXCLUSION AND QUARANTINE RELEASE FORM

Why the Hospital Transfusion laboratory may challenge the use of O D negative blood in an emergency.

Clinical Aspect and Application of Laboratory Test in Herpes Virus Infection. Masoud Mardani M.D,FIDSA

Objectives. Outline. Section 1: Interaction between HIV and pregnancy. Effects of HIV on Pregnancy. Section 2: Mother-to-Child-Transmission (MTCT)

CMV. Your questions answered. Contact us on us Visit December 2013 Edition

Fecal shedding of rotavirus vaccine in premature babies in the neonatal unit

Cord Blood Bankers are. Angie Yost, MT(ASCP) CM 2016 ASCLS-MO CLMA Spring Meeting

SEVENTH EDITION CHAPTER

Hematopoietic Stem Cell Therapy

12 Dynamic Interactions between Hematopoietic Stem and Progenitor Cells and the Bone Marrow: Current Biology of Stem Cell Homing and Mobilization

New Advances in Transfusion EM I LY CO BERLY, M D

DWI assessment of ischemic changes in the fetal brain

QUICK REFERENCE Clinical Practice Guide on Red Blood Cell Transfusion

A summary of guidance related to viral rash in pregnancy

Hot Topics in Tissue Safety

HYPERIMMUNOGLOBULIN and CMV- DNAemia IN PREGNANT WOMEN WITH PRIMARY CYTOMEGALOVIRUS INFECTION

Health Care Worker (Pregnant) - Infectious Diseases Risks and Exposure

Southern Derbyshire Shared Care Pathology Guidelines. Varicella Zoster Virus (VZV)

Transcription:

Neonatal Transfusion: Irradiation and CMV 6 th Annual Blood Matters Conference November 6 th, 2015

Disclosures Member of NAC (National Advisory Committee on Blood and Blood Products) Co-investigator CBS Small Project Fund Transfusion Transmitted CMV in Solid Organ Transplant Recipients

AHS / Stollery Edmonton Neonates Zone- Definitions Birth to 4 months, regardless of gestational age Pediatric Patient Less than 16 years of age On an annual basis, >20 000 transfusions occur between the two NICUs, the intermediate care nursery and our PICU.

Irradiation i

Irradiation Gamma irradiation at 2500 rads/cgy renders lymphocytes incapable of mitosis and thus unable to proliferate preventing Transfusion Associated-GVHD Irradiation of PRBC will decrease outdate to 28 days post irradiation must wash within 24 hours of irradiation for neonatal transfusion due to concern for increased potassium levels

Irradiation Generally Accepted indications: Intrauterine or post IUT exchange transfusion Directed donation/hla matched Includes platelets! l t T Cell immune deficiency Includes Congenital Cardiac anomalies Hodgkin lymphoma BM or SC transplantation (allo & auto) Purine analog therapy (ie. fludarabine) low birth weight babies (<1200g) BCSH Guidelines on the use of irradiated blood components BJH 2010 A&NZ Society of Blood Transfusion Guidelines for Prevention of Transfusion Associated Graft versus Host 2011

What do we do in Edmonton? We irradiate for: Intrauterine nru rn or rpost IUT exchange transfusion rnfu n Directed donation/hla matched products Includes platelets! T Cell immune deficiency Includes Complex Congenital Cardiac anomalies Up to 6 months of age at which time thymic presence or testing for 22q11.2 2 is should be completed Hodgkin lymphoma BM or SC transplantation (allo & auto) Purine analog therapy (ie. fludarabine)

What do we do in Edmonton? We do not irradiate for: Exchange transfusion that are not post IUT Neonatal top up transfusions regardless of gestational age or birth weight

Why? Neonatologist concerns: 1. Hyperkalemic arrest No irradiator on site at the Royal Alexandra site where the medical NICU is. Holding pre irradiated units will increase the potassium 2. Delay in transfusion versus Increased donor exposure We have transfusion policy to provide a limited donor program in eligible neonates To ship aliquots to University Hospital for irradiation has a turn around time of at least 4 hours

For top up transfusions, attempts are made to limit donor exposure by designating an allogeneic red cell unit to an infant for it s 42 day lifespan Red cell aliquots are obtained using Ped-Paks or by sterile docking additional bags to the parent unit

Data from 2011- Jan 31 st 2012 539 red blood cell transfusions in 107 neonates. Percentage of Red Blood Cell Units Transfused to Neonates Between 1Aug2011 and 31Jan2012 n=208 39% Splits Parent Packs 56% Adult Units n=302 5% n=29

Donor Exposure in Neonates Receiving Only One Donor Unit 60% (32 of 53) of the neonates who were only exposed to the one donor unit took only one split. 40% (21 of 53) of the neonates that were only exposed to one donor unit received multiple splits from the same pack. The average received 2 splits with a range The average received 2 splits with a range of 1 to 8 splits transfused.

No case of TA-GVHD has been identified to date in these patient categories Study is planned to review all neonates for past 5 years and ensure not missing any Historically (before I was a MD!) 1 case in a pediatric B-ALL 1 case in a pediatric congenital cardiac patient

CytoMegaloVirus

CMV Cytomegalovirus is an intracellular DNA virus that can be transmitted by transfusion of leukocytes Many centres have indications for CMV negative cellular components for : Intrauterine/exchange transfusion? Neonates weighing less than 1200g born to seronegative, or unknown status, mothers Seronegative, or unknown status, pregnant women

CMV Negative/Safe CMV Safe = prestorage leukoreduced All cellular products in Canada are prestorage leukoreduced and are considered CMV safe CMV Negative = CMV SERO-negative Misnomer as it only indicates the absence of an antibody response to CMV not the lack of virus. - 0.13% of CMV seronegative units have detectable CMV DNA due to primary seroconversion - window period after infection until antibody screening becomes positive is approximately 6 to 8 weeks. Ziemann M et al Krueger S, Maier AB, Unmack A, Goerg S, Hennig H. High prevalence of cytomegalovirus DNA in plasma samples of blood donors in connection with seroconversion. Transfusion. Nov 2007;47(11):1972-1983

NAC CMV Statement: posted August 2014 "The National Advisory Committee recommends that CMV safe and CMV IgG seronegative products be considered equivalent for the majority of patient populations including adult and pediatric Hematopoietic stem cell recipients, CMV seronegative patients t who may require future transplant t and immunodeficient patients. Due to significant controversy and lack of evidence on the need for the provision of CMV seronegative products in addition to leukodepletion in the following 3 patient groups - intrauterine transfusion, neonates under 28 days of age and in elective transfusion of CMV seronegative pregnant women, NAC recommends to follow local policies".

New evidence? Further support for the first part of the NAC recommendation

New Evidence?

New evidence?

New Evidence? Poster presentation CST 2015

Variable Practice - Globally

Variable Practice - Canada

Variable Practice - Canada

Revised NAC Statement: Approved October 2015 The National Advisory Committee recommends that CMV safe (leukoreduced) and CMV IgG seronegative products be considered equivalent. White paper to be updated and posted on White paper to be updated and posted on the website as the evidence summary.

Specific considerations in Neonates Role of breast milk Maternal versus Public bank Ongoing g need in IUT situation Better to have NAT tested for CMV!

Questions????